Nucleolin Informations sur la molécule
Molecule Name
Nucleolin
Alias de la molécule
Nucleolin,NCL,Protein C23
Drug Development Progress
Nombre de médicaments cliniques4
Nombre de médicaments commercialisés1
Phase de R&D la plus avancéeApproved
Alias de la cible
NCL，Nucleolin，Protein C23，Nsr1，C23
Contexte de la molécule
Nucleolin is the major nucleolar protein of growing eukaryotic cells. It is found associated with intranucleolar chromatin and pre-ribosomal particles. It induces chromatin decondensation by binding to histone H1. It is thought to play a role in pre-rRNA transcription and ribosome assembly. May play a role in the process of transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats.
Nucleolin Liste de produits
You Have Viewed 0 Of 0 Results
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| IPP-204106 | N6L; Nucant-6L; IPP-204106; IPP-204106N; poyplexed IPP-204106 | Phase 2 Clinical | Immupharma Plc | Neoplasms; Solid tumours | Details |
| AS-1411 | AGRO-100; GR-026-B; AS-1411; ACT-GRO-777 | Phase 2 Clinical | Antisoma, University Of Alabama At Birmingham, University Of Louisville | Neoplasms; Solid tumours | Details |
| Pegylated recombinant human endostatin (Tsinghua University) | M-2ES; CRB-0401 | Phase 1 Clinical | Beijing Proji Pharmaceutical Technology Co Ltd, Beijing Protgen Biotechnology Development Co Ltd, Tsinghua University | Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| APTA-16 | APTA-16; SJP1604 | Phase 1 Clinical | Aptabio Therapeutics Inc | Leukemia, Myeloid, Acute; Liver Neoplasms; Myelodysplastic Syndromes | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human endostatin (Simcere) | YH-16 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Endostar, 恩度, Endu | Mainland China | Carcinoma, Non-Small-Cell Lung | Shandong Xiansheng Zaiming Biopharmaceutical Co Ltd | 2005-09-12 | Ascites; Brain metastases; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Pleural Effusion, Malignant | Details |